Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
Eupraxia Pharmaceuticals announced that three abstracts from their ongoing Phase 1b/2 RESOLVE trial of EP-104GI, a local drug delivery treatment for eosinophilic esophagitis (EoE), will be presented at the American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) 2026 conferences. The data highlight improvements in dysph…